We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection
News

Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection

Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection
News

Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Abbott Introduces RealTime Molecular Assay in Europe for Detection of HPV Infection"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

European clinicians will have a new weapon to combat cervical cancer with the introduction of Abbott Molecular's real-time polymerase chain reaction (PCR) based diagnostic test for human papillomavirus (HPV). The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer.

Unlike other HPV tests, the Abbott RealTime High Risk HPV assay detects the 14 highest risk HPV genotypes and, in the same procedure, can identify women infected with the HPV 16 and HPV 18 genotypes, which account for more than 70 percent of cervical cancer cases.

The assay can identify HPV-infected patients at risk for cervical cancer by combining two diagnostic tools in one test - HPV high-risk screening and viral genotyping.

"The Abbott RealTime HPV assay is a major advance that provides clinicians with three results in one assay: detection of the 14 HPV high risk types as well as genotyping to determine if the highest risk HPV 16 and 18 genotypes are present in the sample," said Jack Cuzick, Ph.D., professor of epidemiology, Barts and the London, Queen Mary's School of Medicine and Dentistry. "Women with abnormal PAP smear test results will know right away if they are at risk for developing cervical cancer. A negative result from this test will assure them with almost 100 percent certainty that cervical cancer will not occur in the next few years."

He added that the Abbott RealTime High Risk HPV assay could save time and money for follow-up testing to confirm or eliminate cervical cancer diagnosis.

In scientific evaluations at clinical sites across Europe, the Abbott RealTime High Risk HPV assay demonstrated specificity of 99.4 percent and sensitivity of 97.5 percent for qualitative detection of the 14 high-risk HPV genotypes.

The new assay uses liquid-based cytology specimens and runs on the Abbott m-Systems - m2000™ for large-volume testing laboratories and m24sp™ or manual for labs performing small- to mid-sized volumes.
Advertisement